HLX05

HLX05 is a **biosimilar** to **cetuximab**, a chimeric monoclonal antibody that targets the **epidermal growth factor receptor (EGFR)**. It acts as an **EGFR antagonist**, inhibiting signal transduction pathways involved in cell proliferation and survival, which are frequently activated in various cancers. HLX05 is being developed primarily for oncology indications, mirroring the therapeutic uses of cetuximab, such as metastatic colorectal cancer and squamous cell carcinoma of the head and neck. HLX05 is being developed by Shanghai Henlius Biotech and is currently in early-stage clinical trials to assess its pharmacokinetics, safety, tolerability, and immunogenicity compared to the reference product, Erbitux (cetuximab)[1][3][5][9].

Brand names

HLX05HLX-05HLX 05

Other names

Anti-EGFR monoclonal antibody 225 biosimilar重组抗EGFR人鼠嵌合单克隆抗体(上海复宏汉霖生物)